Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML

Heidel, Florian H., Bullinger, Lars, Feng, Zhaohui, Wang, Zhu, Neff, Tobias A., Stein, Lauren, Kalaitzidis, Demetrios, Lane, Steve W. and Armstrong, Scott A. (2012) Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell, 10 4: 412-424. doi:10.1016/j.stem.2012.02.017


Author Heidel, Florian H.
Bullinger, Lars
Feng, Zhaohui
Wang, Zhu
Neff, Tobias A.
Stein, Lauren
Kalaitzidis, Demetrios
Lane, Steve W.
Armstrong, Scott A.
Title Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML
Formatted title
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML
Journal name Cell Stem Cell   Check publisher's open access policy
ISSN 1934-5909
1875-9777
Publication date 2012-04
Sub-type Article (original research)
DOI 10.1016/j.stem.2012.02.017
Volume 10
Issue 4
Start page 412
End page 424
Total pages 13
Place of publication Cambridge, MA, United States
Publisher Cell Press
Language eng
Formatted abstract
A key characteristic of hematopoietic stem cells (HSCs) is the ability to self-renew. Genetic deletion of β-catenin during fetal HSC development leads to impairment of self-renewal while β-catenin is dispensable in fully developed adult HSCs. Whether β-catenin is required for maintenance of fully developed CML leukemia stem cells (LSCs) is unknown. Here, we use a conditional mouse model to show that deletion of β-catenin after CML initiation does not lead to a significant increase in survival. However, deletion of β-catenin synergizes with imatinib (IM) to delay disease recurrence after imatinib discontinuation and to abrogate CML stem cells. These effects can be mimicked by pharmacologic inhibition of β-catenin via modulation of prostaglandin signaling. Treatment with the cyclooxygenase inhibitor indomethacin reduces β-catenin levels and leads to a reduction in LSCs. In conclusion, inhibiting β-catenin by genetic inactivation or pharmacologic modulation is an effective combination therapy with imatinib and targets CML stem cells.
Keyword Hematopoietic stem cells
HSC
Leukemia stem cells
LSC
CML
Imatinib
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
Queensland Brain Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 84 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 95 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 14 Sep 2012, 19:10:54 EST by System User on behalf of Queensland Brain Institute